JAK 阻害薬と悪性腫瘍リスク: さまざまな疾患のメタ解析
Ann Rheum Dis. 2023;82(8):1059–1067 doi: 10.1136/ard-2023-224049
The objective of this study was to estimate the association of JAKi with the incidence of malignancy, compared with placebo, TNFi and MTX.
June 2023
バリシチニブは関節リウマチ患者の骨量と力学機能を改善 – 前向き介入BARE BONE 治験結果
Arthritis Rheumatol. 2023 doi 10.1002/art.42617 Epub ahead of print
The results from Simon, et al. show that baricitinib treatment correlates with improvements in bone stiffness. Further improvements were also observed at the end of Week 52, with an increase in estimated failure load and no measurable progression in bone erosion being reported.
Keywords:
May 2023
アダリムマブ治療中にパラドキシカルに発症した難治性掌蹠膿疱症をイキセキズマブで加療: 症例報告
Clin Cosmet Investig Dermatol. 2023;16:879–881 doi 10.2147/CCID.S406164
Ixekizumab, has been shown to be efficacious against paradoxical palmoplantar pustulosis which has been reported following the administration of therapeutic TNFi. Following the increased use of biologic therapies that improve patients’ quality of life are causing paradoxical adverse effects
Keywords:
体軸関節炎患者にいつセクキヌマブを使うか: 抗TNFα 治療前それとも後?
Reumatol Clin. 19 (2023); 175–179 doi 10.1016/j.reumae.2022.03.007
Secukinumab, an IL-17A monoclonal antibody, was shown to have remarkable efficacy for axSpA in the MEASURE 2 and MEASURE 3 trials. Previous studies have concluded that secukinumab was more efficacious in TNFi-naïve patients.
Keywords:
細胞を標的とした生物学的製剤またはJAK阻害薬で治療中の関節リウマチ患者におけるアジュバント添加リコンビナント帯状疱疹ワクチンの免疫原性と安全性: 前向き観察研究
Int JMol Sci 2023;24(8):6967 doi 10.3390/ijms24086967
A prospective observational study showed that recombinant zoster vaccine (RZV) immunogenicity is not impaired in RA patients on JAK inhibitors or anti-cellular bDMARDs.
Keywords:
BMS-986142, 可逆的ブルトンチロシンキナーゼ抑制薬, の関節リウマチに対する評価: フェーズ2, 無作為化, 二重盲検, 用量検討, プラセボ対照, 試験
Lancet Rheumatol 2023;5:e263–73 doi 10.1016/S2665-9913(23)00089-9
Investigators from a phase 2 study concluded that further investigation with BMS-986142 (a novel BTK) in people with RA is not necessary.
Enthesitis in Patients with Psoriatic Arthritis Treated with Secukinumab or Adalimumab: a post hoc Analysis of the EXCEED Study
Rheumatology (Oxford).2023;kead181. doi 10.1093/rheumatology/kead181.
Results from the 52-week phase 3 EXCEED study showed that secukinumab and adalimumab both display similar efficacy in time to resolution of enthesitis, in patients with PsA, irrespective of baseline enthesitis severity and individual site distribution.
Keywords:
セクキヌマブはPsA患者で持続的寛解と低疾患活動性とともに身体機能を改善し関節破壊を抑制する: フェーズ 3 FUTURE 5 試験の2年データ
RMD Open 2023;9:e002939 doi 10.1136/rmdopen-2022-002939
Results from the 2-year phase 3 study FUTURE 5 show that the majority of patients with PsA who are treated with secukinumab were able to achieve sustained low disease activity or remission by week 104.
Keywords:
April 2023
2つの異なるトファシチニブ治療グループのTNF阻害薬に対する相対リスク: オープンラベル無作為化試験のORAL Surveillance
Ann Rheum Dis. 2023;82(7):901-910 doi: 10.1136/ard-2022-223715
Findings from a post hoc analysis of ORAL Surveillance can help guide individualised benefit/risk assessment and clinical decision-making on treatment with tofacitinib, based on identification of subpopulations ‘at risk’.
Keywords:
生物学的または分子標的抗リウマチ薬治療中の 関節リウマチ患者の間質性肺疾患の罹患率
JAMA Netw Open. 2023;6(3):e233640 doi: 10.1001/jamanetworkopen.2023.3640
Retrospective cohort study results suggest that treatment with tofacitinib, and perhaps other JAK inhibitors, may provide a benefit in reducing the risk of developing RA-Interstitial Lung Disease (ILD).